Gene

Kelonia Therapeutics to Participate in Upcoming Scientific Conferences

Retrieved on: 
Thursday, May 2, 2024
Oncology, Health, Genetics, Other Science, Science, Pharmaceutical, Biotechnology, Kélonia, Multiple myeloma, Date, Ex vivo, Cell, Protein, Patient, Gene, Society, PEGS, Medicine, Therapy, BCMA, Pharmaceutical industry

“Preclinical data continues to demonstrate exquisite T cell specificity and profound CAR T cell activity with low dose levels of our in vivo Gene Placement System (iGPS®),” said Kevin Friedman, Ph.D., Chief Executive Officer and Founder of Kelonia.

Key Points: 
  • “Preclinical data continues to demonstrate exquisite T cell specificity and profound CAR T cell activity with low dose levels of our in vivo Gene Placement System (iGPS®),” said Kevin Friedman, Ph.D., Chief Executive Officer and Founder of Kelonia.
  • “Combining this platform with our proprietary, fully-human, and highly active BCMA CAR candidate creates a medicine with the potential to transform the treatment of multiple myeloma.
  • With KLN-1010 poised to be the first in vivo CAR-T cell therapy for multiple myeloma, we aim to provide a potentially life-changing solution for patients that need it most.
  • ET
    PEGS Boston Summit – Therapeutics: In Vivo Cell and Gene Engineering
    Date and Time: Friday, May 17, 2024 at 9:30 – 10:00 a.m.

Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP

Retrieved on: 
Thursday, May 2, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Medical Devices, Genetics, Consistency, Gold standard, Roadmap, Doctor of Philosophy, Cell, AAV, Quality, CGT, CDMO, Booth, Discovery, Patient, Gene, Society, Good manufacturing practice, CRL, LVV, GMP, Annual general meeting, Final product, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to streamline Cell and Gene Therapy (CGT) research and development as it scales to Good Manufacturing Practice- (GMP) quality.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to streamline Cell and Gene Therapy (CGT) research and development as it scales to Good Manufacturing Practice- (GMP) quality.
  • Moving towards a gold standard for reference materials, Charles River is introducing six AAV reference material serotypes, offering superior empty and full capsid ratios and high vector genome concentration (GC/mL), plus five LVV reference material products, available with different combinations of promoters and reporter genes.
  • Charles River will officially launch its AAV and LVV reference materials with supporting case study data during the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, May 7 – 11, 2024, in Baltimore, MD.
  • We look forward to showcasing our robust portfolio and supporting data during the ASGCT Annual Meeting.” – Ramin Baghirzade, PhD, Senior Director, Global Head Commercial, Gene Therapy CDMO Services, Charles River

Affini-T Therapeutics to Present Data From Its Preclinical Programs Targeting KRAS G12D and TP53 R175H at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Retrieved on: 
Wednesday, May 1, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Cancer, HLA, MD, Cell, Data, Patient, TP53, Gene, Society, LOH, MHC, LVV, Annual general meeting, TCR, Therapy, Vaccine

Affini-T Therapeutics, Inc. , a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that data from its preclinical gene edited HLA-A*11:01 KRAS G12D (AFNT-212) and HLA-A*02:01 TP53 R175H T Cell Receptor (TCR) T cell therapy products for the treatment of solid cancers will be presented at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting held in Baltimore, MD May 7-11.

Key Points: 
  • Affini-T Therapeutics, Inc. , a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that data from its preclinical gene edited HLA-A*11:01 KRAS G12D (AFNT-212) and HLA-A*02:01 TP53 R175H T Cell Receptor (TCR) T cell therapy products for the treatment of solid cancers will be presented at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting held in Baltimore, MD May 7-11.
  • “Our mission is to address the significant unmet needs of patients with hard-to-treat solid tumors by advancing precision immunotherapies that target oncogenic driver mutations,” said Loïc Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics.
  • “We believe that our non-viral targeted knock-in platform, THRIVETM, will enable us to cost-effectively engineer safe and effective T cell therapy products.
  • “TCR based therapies targeting cancer driver mutations recognize the human leukocyte antigen (HLA)/peptide complex on tumor cells,” said Dirk Nagorsen, M.D., Chief Medical Officer at Affini-T Therapeutics.

Reliant Home Run Derby with Dallas Cowboys Scores $145,000 to North Texas Nonprofits

Retrieved on: 
Thursday, May 2, 2024
Baseball, Utilities, Sports, Football, Energy, Philanthropy, Fund Raising, Foundation, Salvation Army brass band, Radio, The Salvation Army, Dallas Cowboys, Sport, Reliant, Dallas Cowboys Cheerleaders, NBC, Gene, Cowboy, Organic, Student, Team Hoyt, Organization

The event featured appearances from mascots Hugo (Reliant), Rowdy (Cowboys) and Shieldy (The Salvation Army).

Key Points: 
  • The event featured appearances from mascots Hugo (Reliant), Rowdy (Cowboys) and Shieldy (The Salvation Army).
  • The national anthem was performed by The Salvation Army Band, while the Dallas Cowboys Cheerleaders and Chowboyz also joined in the fun.
  • “The Reliant Home Run Derby brings us together to swing for the fence and raise funds for a good cause.
  • The eighth annual Reliant Media League featured 12 North Texas reporters from local TV, radio, print and online outlets.

Forge Biologics Announces Nine Presentations at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Retrieved on: 
Tuesday, April 30, 2024
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Krabbe disease, Patient, Gene, Cell, Society, AAV, Pharmaceutical industry

Forge Biologics, a member of Ajinomoto Bio-Pharma Services and leading manufacturer of genetic medicines, today announced that it will deliver nine presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27thAnnual Meeting, taking place May 7-11, 2024, in Baltimore, Maryland.

Key Points: 
  • Forge Biologics, a member of Ajinomoto Bio-Pharma Services and leading manufacturer of genetic medicines, today announced that it will deliver nine presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27thAnnual Meeting, taking place May 7-11, 2024, in Baltimore, Maryland.
  • The presentations include a late-breaking oral presentation, three technical session presentations, and five scientific posters spanning Forge’s process development, molecular development, integrated regulatory services, and clinical program advancements.
  • “We are also especially encouraged by a late-breaking oral presentation that our Chief Medical Officer, Dr. Maria Escolar, will be delivering that provides a clinical update on FBX-101 where all five patients with Krabbe disease receiving Forge’s gene therapy are walking—a remarkable result.
  • Forge Biologics will be at booth #827 in the Exhibitor Hall.

SonoThera™ to Present Four Abstracts at the 2024 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Retrieved on: 
Tuesday, April 30, 2024
Biotechnology, Health, Genetics, Science, Research, Gene, Kidney, Abstract, Doctor of Philosophy, Cell, DNA, Liver, Society, Gene expression, NHP, Vaccine

SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases through genetic therapy, today announced that it will present four abstracts at the 27th annual meeting of the American Society of Gene and Cell Therapy ( ASGCT ) taking place in Baltimore, Maryland, May 7-11, 2024.

Key Points: 
  • SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases through genetic therapy, today announced that it will present four abstracts at the 27th annual meeting of the American Society of Gene and Cell Therapy ( ASGCT ) taking place in Baltimore, Maryland, May 7-11, 2024.
  • All four presentations feature SonoThera’s ultrasound-guided nonviral gene therapy platform, which is being developed to non-invasively deliver nucleic acid payloads of diverse formats and sizes.
  • Title: Targeted non-viral gene delivery through transcutaneous ultrasound enables rapid, robust, redosable, titratable, and durable gene expression in the liver in murine and NHP models.
  • Title: Cellular phenotyping of non-human primate and mouse kidney and liver following a novel targeted transcutaneous ultrasound-mediated gene delivery demonstrates gene expression in clinically relevant cell types.

Global Clinical Biomarkers Industry Research, 2023-2024 & 2033 - Discovery of Novel Biomarkers Expanding Precision Medicine Horizons, Increase in Industrial Activity in Clinical Biomarker Landscape - ResearchAndMarkets.com

Retrieved on: 
Monday, April 29, 2024
Health, Oncology, Biometrics, Breast cancer, Cancer, Genomics, Investment, Lung cancer, Blood, Prognosis, Malignancy, Infection, Region, Software, TPA, PSA, Glycoprotein, Research, NGS, Prostate cancer, ChromeOS, SSC, Serum, Thermo Fisher Scientific, Diagnosis, Drug discovery, Biomarker, Neoplasm, EGFR, Biotechnology, Growth, Gene, Medical imaging

The global clinical biomarkers market is a highly fragmented market, with many smaller and private companies constantly entering the market.

Key Points: 
  • The global clinical biomarkers market is a highly fragmented market, with many smaller and private companies constantly entering the market.
  • Key players in the clinical biomarkers market analyzed and profiled in the study involve established players that offer various kinds of products and services.
  • As per this research, the global clinical biomarkers market includes manufacturers and service providers offering proprietary biomarkers testing products and services for clinical diagnostics and research purposes.
  • Based on product, the global clinical biomarkers market was led by the product segment, with a 76.59% share in 2022.

Asimov Achieves 10x Improvement in Lentiviral Production, Launches New Stable Cell Line Development Service

Retrieved on: 
Monday, April 29, 2024
Infectious Diseases, Genetics, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Immortalised cell line, Risk, Transgene, Kernel, Therapy, Lentivirus, Synthetic biology, GMP, Transfection, Gene, Vaccine

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the expansion of its LV Edge System with the launch of a fully stable cell line development service.

Key Points: 
  • Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the expansion of its LV Edge System with the launch of a fully stable cell line development service.
  • The new, fully-stable LV Edge Producer cell line development service, which generates clones that achieve E9 TU/mL with no transient transfection required.
  • The development of a fully stable cell line technology enables scalable, reproducible and low-cost production of lentivirus, which will unlock applications for larger therapeutic indications.
  • The service takes less than 6 months from sequence transfer to a stable, clonal cell line and is performed in Asimov’s Boston cell line development facility.

Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)

Retrieved on: 
Thursday, April 11, 2024
Education, Safety, Gene silencing, Disease, Cell, PD-1, NCT, Gene, Society, Clinical trial, Vaccine

Preclinical studies demonstrate that PH-762 is effective in silencing PD-1, boosting immune response, and inhibiting tumor growth.

Key Points: 
  • Preclinical studies demonstrate that PH-762 is effective in silencing PD-1, boosting immune response, and inhibiting tumor growth.
  • PH-762 is currently being studied in a U.S. clinical trial to assess safety and efficacy in specific skin cancers (NCT 06014086).
  • The data will be presented at the American Society of Cell and Gene Therapy (ASCGT) on May 8th in Baltimore, Maryland.
  • The mission of ASGCT is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease.

Sania Therapeutics to Present at the American Society of Gene & Cell Therapy Annual Meeting

Retrieved on: 
Thursday, April 11, 2024
Abstract (summary), Therapy, Gene, Cell, Society

LONDON, UK & NEW YORK, USA – 11 April 2024, Sania Therapeutics (the “Company”), focused on developing targeted genetic medicines for prevalent disorders today announces that it will be presenting three posters at the American Society of Gene & Cell Therapy 2024 Annual Meeting, taking place from 7-11 May 2024 in Baltimore, MD.

Key Points: 
  • LONDON, UK & NEW YORK, USA – 11 April 2024, Sania Therapeutics (the “Company”), focused on developing targeted genetic medicines for prevalent disorders today announces that it will be presenting three posters at the American Society of Gene & Cell Therapy 2024 Annual Meeting, taking place from 7-11 May 2024 in Baltimore, MD.
  • Further details are below.
  • Abstracts details will be shared in due course and the posters will be made available on Sania’s website following their presentation.